ClinicalTrials.gg
Not yet recruitingNCT06336161Updated Mar 28, 2024

Comparison Between Ultrasound-Guided Erector Spinae Plane Block Versus Ultrasound-Guided Caudal Injection

An interventional study of Fentanyl in Postoperative Pain, sponsored by Al-Azhar University. Not yet recruiting at 1 site in Egypt. Open to participants aged 21 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-03-28.

Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 47 studies testing fentanyl in Pain, Postoperative — 5 open to participants now, 6 under way, none of them phase 3. Fentanyl · Pain, Postoperative.

Planned enrollment
24th of 47
80 · median 80
Started
2024
with 5 others
No phase
12 of 47
2 open now
Registered
38th of 47
by date
Lead sponsor
1 of 47
Al-Azhar University

Among the 47 studies testing fentanyl in Pain, Postoperative, this one is the 24th largest by planned enrollment, is one of 6 that started in 2024, is one of 12 with no phase, and was the 38th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

5 of the 47 studies testing fentanyl in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About fentanyl

Fentanyl: first FDA approval 1968 (SUBLIMAZE PRESERVATIVE FREE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 21 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing fentanyl in Pain, Postoperative, or all of them as a file.
02

Study summary

Patient-controlled analgesia is typically used to relieve postoperative pain. Patient-controlled analgesia, on the other hand, is prone to opioid-related side effects. Furthermore, standard postoperative analgesia has a limited analgesic impact. If postoperative lumbosacral spine pain is not successfully treated, it can progress to chronic pain, compromising patients' quality of life.

The methods of access for epidural injections are characterized as transforaminal, interlaminar, or caudal. Caudal epidural injections (CEI) are often utilized as a diagnostic or therapeutic tool in a range of lumbosacral-originating spinal pain problems, and they are especially useful in patients with complicated lumbar epidural access diseases, such as post laminectomy syndrome. It is regarded as a very simple treatment in the realm of interventional pain management, and it is also recognized to have a reduced risk of inadvertent Dural puncture than other epidural techniques

Read the detailed description

Patient-controlled analgesia is typically used to relieve postoperative pain. Patient-controlled analgesia, on the other hand, is prone to opioid-related side effects. Furthermore, standard postoperative analgesia has a limited analgesic impact. If postoperative lumbosacral spine pain is not successfully treated, it can progress to chronic pain, compromising patients' quality of life.

Major lumbosacral surgery results in considerable postoperative discomfort that normally lasts at least three days. According to several research, the most discomfort occurs in the first four postoperative hours and gradually decreases by the third postoperative day. Efficient and safe postoperative analgesic treatments following lumbosacral surgery are useful for early recovery and hence required.

Traditional caudal epidural injections, on the other hand, pose a potential risk of epidural venous plexus or dura penetration, with the incidence of accidental intravascular injections, as confirmed by contrast enhanced fluoroscopy, ranging from 11 to 42% in patients who had received caudal epidural injections. Furthermore, there have been a few instances of unintended Dural puncture during the caudal approach because of an unusually low Dural sac termination in the sacral canal.

Such complications of intravascular and intrathecal drug injections might result in systemic toxicity of local anesthetics and complete spinal anesthesia. Thus, ultrasonography (US) can be utilized to guide caudal injections, increasing the efficacy of pain treatment while decreasing the risk of complications and incorrect injections. Previous investigations shown the feasibility of using ultrasound to locate the sacral hiatus and guide the needle into the caudal epidural area, with a reported success rate of 100%.

Another technique for postoperative pain relief is the Erector spinae plane block (ESPB), which was introduced in 2016. It is a relatively new regional anesthesia technique in which local anesthetic is injected into the fascial plane between the transverse process of the vertebra and the erector spinae muscles. It has acquired favor in perioperative analgesia for a variety of surgical procedures, including breast, thoracic, abdominal, and lumbar spine operations.

The addition of US to ESPB allows the needle to be guided to efficiently deposit the anesthetic agents deep to the erector spinae muscle, resulting in the blockage of the ventral and dorsal rami of many spinal neurons, boosting the efficiency of pain control.

03

Conditions studied

  • Postoperative Pain

Browse trials for

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing lumbosacral spine surgeries from (L4-L5) level to end of spinal cord.
  • ' classification (ASA) I \& II.

Exclusion criteria

Exclusion Criteria:

  • Patient's refusal.
  • History of any previous back surgeries.
  • History of any spinal cord deformities e.g., Scoliosis, Lordosis, Kyphosis, Ankylosing Spondylitis
  • Bleeding disorders ( count \< 80,000; >1.4; PC\< 70%) and coagulopathies.
  • Skin lesion, wounds, or infection at the injection site.
  • Known allergy to local anesthetic drugs.
  • Peripheral and Central Neuropathy.
  • Patients with pre-operative opioid consumption.
  • Chronic opioids or analgesics users.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Group A ( Erector Spinae Plane Block)

    About 40 patients who will be subjected to Ultrasound-Guided Erector Spinae Plane Block.for Postoperative Pain Management

    Drug: Fentanyl

  • Active comparator
    Group B (Caudal Injection)

    About 40 patients who will be subjected to Ultrasound-Guided Caudal Injection in Lumbosacral Spine Surgeries for Postoperative Pain Management

    Drug: Fentanyl

Interventions

  • to compare between Ultrasound-Guided ESPB and Ultrasound-Guided CEI for postoperative pain relief in patients who underwent lumbosacral surgeries.

    Also known as: propofol 2Mg/Kg

06

What researchers measure

Primary outcomes

  1. Measurement of Post-operative Pain

    Assessment of Pain after operations will be evaluated using the VAS consisting of a horizontal or vertical line, 10 centimeters long (100 mm) anchored at the extremes by two verbal descriptors referring to the pain status

    Time frame: the first 24 hours postoperatively

07

Study locations

1 site
08

References and documents

Publications

  • Patel Y, Ramachandran K, Shetty AP, Chelliah S, Subramanian B, Kanna RM, Shanmuganathan R. Comparison Between Relative Efficacy of Erector Spinae Plane Block and Caudal Epidural Block for Postoperative Analgesia in Lumbar Fusion Surgery- A Prospective Randomized Controlled Study. Global Spine J. 2025 Mar;15(2):639-647. doi: 10.1177/21925682231203653. Epub 2023 Sep 22. PubMed 37737097 ↗
  • Shah M, Halalmeh DR, Sandio A, Tubbs RS, Moisi MD. Anatomical Variations That Can Lead to Spine Surgery at the Wrong Level: Part III Lumbosacral Spine. Cureus. 2020 Jul 28;12(7):e9433. doi: 10.7759/cureus.9433. PubMed 32864257 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2024; primary completion for Apr 2025, 12 months later.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 12 months is close to that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2024
First posted
Mar 28, 2024
StartEst.
Apr 1, 2024
Primary completionEst.
Apr 1, 2025
CompletionEst.
May 1, 2025
Last update
Mar 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06336161
Responsible party
Mohamed Khalil Elsayed Khalil (Cairo,Egypt, Al-Azhar University) — Principal investigator
First posted
Mar 28, 2024
Start date
Apr 1, 2024 (estimated)
Primary completion
Apr 1, 2025 (estimated)
Completion
May 1, 2025 (estimated)
Last update
Mar 28, 2024

Study contacts

Mohamed Khalil, Resident
Contact
khalil.mohamed24mkh@gmail.com
+201001297071
Othman Yahia, Lecturer
Contact
khalil.mohamed24mkh@gmail.com
+201001297071
Tarek Monir, Professor
study chair · Anesthesiology, Intensive care, and Pain Management, Faculty of Medicine, Al-Azhar University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fentanyl

Start the discussion